[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 20, Issue 2 (Bimonthly 2016) ::
Feyz 2016, 20(2): 180-187 Back to browse issues page
Survival analysis of breast cancer cases under the regimens of anthracycline alone and combinaed with taxanes (2004-2012)
Majid Ehsani, Fatemeh Atoof *, Neda Nasri
Department of Biostatistics and Epidemiology, Faculty of Health, Kashan University of Medical Sciences, Kashan, I. R, Iran. , atoof@alumnus.tums.ac.ir
Abstract:   (1867 Views)

Background: Breast cancer (BC) is the most common cancer among women. Early diagnosis, treatment and prevention of BC is among the most debated topics in the world. Early diagnosis and appropriate treatment of BC can decrease the mortality rate to 2.2% per year. The aim of this study was to analyze the survival of patients with BC treated with anthracycline alone and combined to Taxane.

Materials and Methods:  In this historic cohort study the BC cases (n=160) referred to oncology clinics during 2004-2012 were divided to two treatment groups (Anthracycline alone and Anthracycline+Taxane). Patients were followed-up until death or exclusion from    study. On demand, every 6 months a bone scan and CT was taken; every 3 months using blood tests the cases were followed-up. The samples were analyzed for estrogen, progesterone and HER2 Neu receptor and then survival analysis.

Result:  All cases (n=160) were divided into two equal treatment groups (Mean age: 47.4 years). While no significant difference was  found between the two groups for age, estrogen, progesterone, HER2 Neu receptor, size/type of tumor, number of lymph node and metastasis rate, the mortality and exacerbation rates in Anthracycline group (12.5% and 7.5%, respectively) was significantly higher compared to Taxane group (3.8% and 0, respectively). In addition, the survival rate in Taxane group was higher.

Conclusions:  Use of Taxane for BC reduces the mortality and exacerbation rates but increases its survival rate and life expectancy.

Keywords: Survival rate, Anthracycline, Taxane, Breast cancer
Full-Text [PDF 277 kb]   (852 Downloads)    
Type of Study: Research | Subject: medicine, paraclinic
Received: 2016/06/16 | Accepted: 2016/06/16 | Published: 2016/06/16
References
1. Vincent T, DeVita Jr, Theodore S, Lawrence MD, Steven A, Rosenberg MD, et al. Devita‚ Hellman‚ Rosenberg Cancer: principles and practice of oncology. 10th ed. Wolters Kluwer; 2015. p. 1117-56.
2. Skeel R. Handbook of cancer chemotherapy. 6th ed. New York: Lippincott Williams and Wilkins Co; 2003.
3. Casciatice Dennis A, Lowitz Barry B. Mannual of clinical oncology. 4th ed. Spiral-bound; 2000. p. 218-37.
4. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel But Not from Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patient with Node- positive Primary Breast Cancer. J Clinical Oncol 2003; 21(6): 976-83.
5. Chen WW, Chang DY, Huang SM, Lin CH, Hsu C, Lin MH, et al. The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: a comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast 2013; 22(6): 1148-54.
6. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26(1): 44-53.
7. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007; (4): CD004421.
8. Henderson IC1, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976–83.
9. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23(16): 3686-96.
10. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24(36): 5664–71.
11. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100(2): 121–33.
12. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100(11): 805-14.
13. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16(11): 1762–71.
14. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008; 26(25): 4092–9.
15. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009; 373(9676): 1681-92.
16. Rocca A, Bravaccini S, Scarpi E, Mangia A, Petroni S, Puccetti M, et al. Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Res Treat 2014; 144(2): 307-18.
17. Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006; 20(2): 135-43.
18. Benz CC. Import of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008; 66(1): 65-74.
19. Shao W, Brown M. Advances in estrogen receptor biology prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004; 6(1): 39-52.
20. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone independent effects of human progesterone receptors (PR) in estrogen receptor positive breast cancer PR isoform specific gene regulation and tumor biology. Mol Endocrinol 2005; 19(3): 574-87.
21. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, et al. Clinical Significance of Akt and Her2/neu over expression in African and Latina women with breast cancer. Breast Cancer Res 2008; 10(1): R3.
22. Fleishman SJ, Schlessinger J, Ben-Tal N. Aputative molecular activation switch in the trans membrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99(25): 15937-40.
23. Lo HW, Hang MC. Nuclear EGFR signaling network in cancers linking EGFR pathway to cell cycle progression nitric oxide pathway and patient survival. Br J Cancer 2007; 96 Suppl: R16-20.
24. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, et al. Dawood S, et al. Prognostic significance of Her2 status in women with inflammatory breast cancer. Cancer 2008; 112(9): 1905-11.
25. Glöckner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c - myc and cyclinD, but not of c - erbB2 amplification in breasr cancer. Lab Invest 2002; 82(10): 1419-26.
26. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, et al. HER2 testing in breast cancer NCCN Task Force neport and recommendations. J Natl Compr Canc Netw 2006; 4 Suppl 3: S1-22.
27. Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008; 13(5): 515-25.
28. Marty M, Cognetti F, Maraninchi D et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006; 100(Suppl 1): S103.
29. Wardley A, Anton-Torres A, Pivot X, et al. Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/ metastatic breast cancer: First efficacy results from the Phase II MO16419 (CHAT) study. Breast Cancer Res Treat 2006; 100(Suppl 1): S101.
30. Pegram M, Forbes J, Pienkowski T et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: 968S.
31. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and Taxane–Trastuzumab Combinations in MBC paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786 -92.
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783–92.
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ehsani M, Atoof F, Nasri N. Survival analysis of breast cancer cases under the regimens of anthracycline alone and combinaed with taxanes (2004-2012). Feyz. 2016; 20 (2) :180-187
URL: http://feyz.kaums.ac.ir/article-1-3031-en.html


Volume 20, Issue 2 (Bimonthly 2016) Back to browse issues page
مجله علمی پژوهشی فیض ::: دانشگاه علوم پزشکی کاشان KAUMS Journal ( FEYZ )
Persian site map - English site map - Created in 0.05 seconds with 32 queries by YEKTAWEB 3925